Split-Indication Agreements: Happy Unions Or Problematic Proposals?

Greater restrictions on off-label promotions and continued cost pressures are creating an environment ripe for alliances based around single products with split indications, industry executives said during the Windhover Pharmaceutical Strategic Outlook conference in New York March 27-29